Fresenius Sells Controlling Stake in Vamed Rehab Business to PAI [BNN Bloomberg (Canada)]
Institutions own 30% of Fresenius SE & Co. KGaA (ETR:FRE) shares but retail investors control 43% of the company [Yahoo! Finance]
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP [Yahoo! Finance]
Fresenius Targets Faster Earnings Growth After More Cost Cuts [BNN Bloomberg (Canada)]